ASX - By Stock
|
CYP |
Re:
Ann: FUJIFILM Cellular Dynamics Executes Manufacturing Agreement
|
|
elvisj
|
153 |
27K |
14 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
153
|
27K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: FUJIFILM Cellular Dynamics Executes Manufacturing Agreement
|
|
elvisj
|
153 |
27K |
6 |
09/01/22 |
09/01/22 |
ASX - By Stock
|
153
|
27K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: New Study to Investigate the High Potency of Cymerus MSCs
|
|
elvisj
|
65 |
15K |
9 |
12/12/21 |
12/12/21 |
ASX - By Stock
|
65
|
15K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: New Study to Investigate the High Potency of Cymerus MSCs
|
|
elvisj
|
65 |
15K |
6 |
12/12/21 |
12/12/21 |
ASX - By Stock
|
65
|
15K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Phase 3 Osteoarthritis Clinical Trial Commences
|
|
elvisj
|
394 |
84K |
6 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
394
|
84K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Phase 3 Osteoarthritis Clinical Trial Commences
|
|
elvisj
|
394 |
84K |
1 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
394
|
84K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Phase 3 Osteoarthritis Clinical Trial Commences
|
|
elvisj
|
394 |
84K |
1 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
394
|
84K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
7 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
512
|
116K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
5 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
512
|
116K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
2 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
512
|
116K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
5 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
512
|
116K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
10 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
512
|
116K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
elvisj
|
2.1K |
676K |
8 |
24/10/21 |
24/10/21 |
ASX - By Stock
|
2.1K
|
676K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
elvisj
|
2.1K |
676K |
11 |
23/10/21 |
23/10/21 |
ASX - By Stock
|
2.1K
|
676K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
elvisj
|
2.1K |
676K |
8 |
23/10/21 |
23/10/21 |
ASX - By Stock
|
2.1K
|
676K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Receives US$5m Fujifilm Fee
|
|
elvisj
|
39 |
7.3K |
6 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
39
|
7.3K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Enters into a New Strategic Partnership with Fujifilm
|
|
elvisj
|
249 |
53K |
11 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
249
|
53K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Enters into a New Strategic Partnership with Fujifilm
|
|
elvisj
|
249 |
53K |
6 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
249
|
53K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Enters into a New Strategic Partnership with Fujifilm
|
|
elvisj
|
249 |
53K |
14 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
249
|
53K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
elvisj
|
183 |
37K |
9 |
26/07/21 |
26/07/21 |
ASX - By Stock
|
183
|
37K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
elvisj
|
183 |
37K |
10 |
25/07/21 |
25/07/21 |
ASX - By Stock
|
183
|
37K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
elvisj
|
183 |
37K |
6 |
24/07/21 |
24/07/21 |
ASX - By Stock
|
183
|
37K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Ethics Approval for Cynata's Clinical Trial in DFU
|
|
elvisj
|
63 |
14K |
13 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
63
|
14K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Stuart Robert's Pitt Street Report
|
|
elvisj
|
289 |
47K |
8 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
289
|
47K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Stuart Robert's Pitt Street Report
|
|
elvisj
|
289 |
47K |
8 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
289
|
47K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata to Present at MST Access Investor Conference 15 June
|
|
elvisj
|
19 |
4.8K |
10 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
19
|
4.8K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial
|
|
elvisj
|
495 |
107K |
5 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
495
|
107K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial
|
|
elvisj
|
495 |
107K |
3 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
495
|
107K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial
|
|
elvisj
|
495 |
107K |
6 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
495
|
107K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Cynata in 10
|
|
elvisj
|
200 |
42K |
5 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
200
|
42K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Cynata in 10
|
|
elvisj
|
200 |
42K |
6 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
200
|
42K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
9 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
512
|
116K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
6 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
512
|
116K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
elvisj
|
512 |
116K |
5 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
512
|
116K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
elvisj
|
183 |
37K |
6 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
183
|
37K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Enrolled in Cynata MEND Clinical Trial
|
|
elvisj
|
183 |
37K |
7 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
183
|
37K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial
|
|
elvisj
|
495 |
107K |
10 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
495
|
107K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
CYP on 9 NEWS
|
|
elvisj
|
32 |
8.6K |
7 |
20/05/21 |
20/05/21 |
ASX - By Stock
|
32
|
8.6K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
|
|
elvisj
|
221 |
49K |
8 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
221
|
49K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
|
|
elvisj
|
221 |
49K |
5 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
221
|
49K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
|
|
elvisj
|
221 |
49K |
6 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
221
|
49K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Expands trial in COVID-19 & Respiratory Failure
|
|
elvisj
|
221 |
49K |
4 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
221
|
49K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
3 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
99
|
20K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
7 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
99
|
20K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
2 |
10/05/21 |
10/05/21 |
ASX - By Stock
|
99
|
20K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
8 |
10/05/21 |
10/05/21 |
ASX - By Stock
|
99
|
20K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
5 |
10/05/21 |
10/05/21 |
ASX - By Stock
|
99
|
20K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
elvisj
|
99 |
20K |
9 |
10/05/21 |
10/05/21 |
ASX - By Stock
|
99
|
20K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
elvisj
|
1.6K |
460K |
1 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
1.6K
|
460K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
elvisj
|
1.6K |
460K |
4 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
1.6K
|
460K
|
4
|
|